Latest Biotech News

Regulators approved two new oral treatments for uncomplicated gonorrhea, adding zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) to the antibiotic armamentarium. Both agents received priority...

The U.S. House of Representatives passed the INVEST Act, a BIO‑backed bipartisan bill designed to unlock capital for small, innovative firms by removing regulatory hurdles for companies and...

Disco Pharmaceuticals closed a €36 million seed round (final close) to advance its surfaceome discovery platform toward preclinical development. The funding will support target validation and...

Eli Lilly reported jaw-dropping Phase 3 data showing its triple-agonist retatrutide produced mean weight losses approaching 29% in a late-stage study, while trial documents and follow-up reports...

Arcus Biosciences and partners reported a Phase 3 failure for the anti‑TIGIT antibody domvanalimab when added to PD‑1 blockade and chemotherapy, prompting the company to pause multiple...

Swiss biotech AC Immune released interim Phase II biomarker data from its active immunotherapy Vacsyn (ACI‑7104) that the company says show consistent α‑synuclein, neurofilament light (NfL) and...

Two separate initiatives this week underscored the commercial and clinical push to embed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assays into oncology care. Exact Sciences...

Venture financing remained active this week with large rounds and strategic seed closes across geographies. Chinese innovators D3 Bio and Sanegene each secured rounds exceeding $100 million,...

Major industry collaborations continued to shape pipelines: Novartis struck a discovery and development alliance with UK biotech Relation Therapeutics that could deliver up to $1.7 billion in...

Regulatory tensions intensified as an FDA staff analysis on pediatric COVID‑19 vaccine safety was circulated internally and triggered media reports that the agency is weighing unprecedented...

CRISPR and gene‑editing took center stage as leaders framed 2025 as a landmark year of in vivo and personalized editing advances. In a wide‑ranging interview, Jennifer Doudna reflected on recent...

Two collaborations signaled rapid scaling of data and AI infrastructure in discovery research. Parse Biosciences and Tahoe Therapeutics agreed to generate a 300 million cell perturbation atlas to...

Rezolute’s Phase 3 Sunrize study of ersodetug failed to meet its primary and key secondary endpoints in congenital hyperinsulinism, prompting the company to signal program uncertainty and to plan...

Arcus Biosciences and Gilead reported that the Phase 3 program for the anti‑TIGIT antibody domvanalimab missed its primary endpoints, prompting an immediate pause and strategic refocus. The...

Eli Lilly’s triple‑agonist retatrutide delivered unprecedented weight loss in a Phase 3 study—averaging roughly 28.7% at 68 weeks—while also improving knee osteoarthritis pain. The high efficacy...

AC Immune released interim biomarker results from its Phase II Vacsyn trial of the active α‑synuclein vaccine ACI‑7104, reporting changes in cerebrospinal fluid α‑synuclein and supportive...

Rezolute disclosed that its Phase 3 Sunrize study of ersodetug for congenital hyperinsulinism missed primary and key secondary endpoints, prompting management to halt investor guidance and plan...

Exact Sciences presented first data showing its Oncodetect MRD test stratified distant‑recurrence risk in triple‑negative breast cancer in an NSABP B‑59 sub‑study; MRD‑positive patients after...

The FDA proposed reclassifying some companion diagnostic nucleic‑acid tests from Class III to Class II, which would allow select tests to follow the 510(k) pathway instead of the more burdensome...

China’s D3 Bio and Sanegene each closed financing rounds topping $100 million, underscoring continued deep venture activity in Chinese biotech despite geopolitical headwinds. The financings...